Daclatasvir and Peginterferon/Ribavirin for Black/African-American and Latino Patients with HCV infection. [electronic resource]
Producer: 20170227Description: 834-845 p. digitalISSN:- 1665-2681
- Administration, Oral
- Adult
- Black or African American
- Aged
- Antiviral Agents -- adverse effects
- Biomarkers -- blood
- Carbamates
- Drug Therapy, Combination
- Female
- Genotype
- Hepacivirus -- drug effects
- Hepatitis C, Chronic -- diagnosis
- Hispanic or Latino
- Humans
- Imidazoles -- adverse effects
- Interferon-alpha -- adverse effects
- Male
- Middle Aged
- Polyethylene Glycols -- adverse effects
- Puerto Rico
- Pyrrolidines
- RNA, Viral -- blood
- Recombinant Proteins -- adverse effects
- Ribavirin -- adverse effects
- Time Factors
- Treatment Outcome
- United States -- epidemiology
- Valine -- analogs & derivatives
- Viral Load
- Young Adult
No physical items for this record
Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study
There are no comments on this title.
Log in to your account to post a comment.